A blood collection tube

Abstract

The application discloses a blood collection tube, which belongs to the technical field of blood collection equipment and comprises a tube body and a liquid storage assembly. A first opening is arranged on the top side of the tube body, and a cover body is arranged on the first opening. The liquid storage assembly comprises a shell and a communication needle tube. A hollow liquid storage cavity is arranged in the shell, and the liquid storage cavity is used for storing liquid amikacin. The shell is detachably connected to one end of the cover body which is away from the tube body. One end of the communication needle tube is communicated with the tube body. The liquid storage cavity can move relative to the tube body, and the liquid storage cavity can move to the other end of the communication needle tube. Compared with the prior art, the blood collection tube can realize pre-packaging correction of a medicament, and one-time quantitative drug delivery can be completed before blood collection, so that the clinical pain points of traditional post-blood-collection delayed drug addition and poor dissociation effect are solved.

Description

Technical Field

[0001] This invention relates to the field of blood testing equipment technology, and in particular to a blood collection tube. Background Technology

[0002] EDTA (ethylenediaminetetraacetic acid) is the standard anticoagulant recommended by the International Committee for Standardization of Hematology (ICSI) for complete blood cell counts. However, approximately 0.1%–0.2% of patients have EDTA-dependent pseudothrombocytopenia (EDTA-PTCP), where EDTA induces platelet aggregation in vitro, leading to a falsely low count on automated hematology analyzers. This can result in unnecessary bone marrow aspiration, platelet transfusions, or even splenectomy, among other over-medical procedures.

[0003] The existing solution involves adding amikacin to the collected blood sample to dissociate platelet aggregation. However, this method is "added after blood collection," lacking a commercially available, ready-to-use product, and relies on timely addition by the operator—specifically, within 30 minutes of blood collection. Meeting this clinical requirement within 30 minutes—from blood collection and specimen transport to laboratory reception, microscopic confirmation, and drug addition—is practically impossible in practice. If addition is delayed beyond 30 minutes, the intervention of amikacin is severely delayed because by the time it is added, platelet aggregation has already formed or is nearly complete, and amikacin can only attempt to dissociate existing platelet aggregates, resulting in inconsistent effectiveness. Studies have also shown that pre-mixing amikacin with EDTA and drying it on the tube wall reduces its platelet aggregation correction effect over time. This is primarily due to two reasons: first, the freeze-drying process itself may damage the molecular structure of amikacin; second, prolonged contact between amikacin and EDTA during storage leads to chemical interactions, resulting in reduced amikacin activity or structural changes. This indicates that while the pre-mixing and drying method achieves "pre-fixation before blood collection," it fails to address the potential stability issues arising from the long-term coexistence of the two components. Furthermore, in real-world clinical settings, most hospital laboratories do not routinely stock amikacin. On one hand, while hospital pharmacies purchase amikacin as a prescription antibiotic, it is not typically supplied routinely to laboratories; on the other hand, commercially available amikacin products vary in specifications, with some being veterinary preparations of inconsistent concentration and quality. Even laboratories that purchase amikacin themselves face numerous problems, including drug waste due to expiration, improper storage, incorrect concentration calculations, inconsistent dosages, and operational contamination. These practical difficulties have made it difficult to popularize and standardize the "amikacin correction method" in clinical testing, despite its theoretical effectiveness. Therefore, there is an urgent clinical need for a standardized, readily usable, easy-to-use, and stable EDTA-PTCP correction product. Summary of the Invention

[0004] The present invention aims to solve the technical problems existing in the above-mentioned related technologies and proposes a blood collection tube that can effectively reduce platelet aggregation after blood collection from EDTA patients.

[0005] The solution to the technical problem of this invention is: A blood collection tube, comprising: The tube has a first opening on its top side, and a cover is provided on the first opening. A liquid storage assembly includes a housing and a connecting needle tube. The housing has a hollow liquid storage cavity for storing liquid amikacin. The housing is detachably connected to the end of the cap opposite to the tube body. One end of the connecting needle tube is connected to the tube body. The liquid storage cavity is movable relative to the tube body and can be moved to the other end connected to the connecting needle tube.

[0006] This technical solution has at least the following beneficial effects: the liquid storage component and the tube body are placed as a whole. The liquid storage chamber of the liquid storage component serves as a sealed chamber to store liquid amikacin. When the blood collection tube needs to be used for blood collection, the shell containing the liquid storage chamber is moved closer to the connecting needle, allowing the connecting needle to penetrate into the liquid storage chamber, thereby connecting the liquid storage chamber and the tube body. This allows the liquid amikacin in the liquid storage chamber to be introduced into the tube body. Subsequently, the shell and connecting needle are removed from the cap, leaving only the tube body with the cap. At this point, the operator uses a blood collection needle to collect blood into the tube body. When the blood of the person being tested enters the tube body, if the person being tested has EDTA-dependent pseudothrombocytopenia, the collected blood can immediately react with the amikacin inside, preventing platelet aggregation in the blood and thus avoiding affecting the blood test results.

[0007] As a further improvement to the above technical solution, the housing includes a connecting part and a moving part. The connecting part is detachably connected to the cover body, and the connecting needle tube is installed at the connecting part. The moving part is slidably installed on the side of the connecting part away from the cover body. The liquid storage cavity is disposed in the moving part. The end of the connecting needle tube away from the tube body extends out of the connecting part and faces the moving part. The moving part can move to allow the connecting needle tube to penetrate into the liquid storage cavity.

[0008] By adopting the above technical solution, the shell is divided into a connecting part and a moving part. Before blood collection begins, the operator only needs to press the moving part and push it towards the connecting part, so that the connecting needle installed on the connecting part is inserted and connected to the liquid storage chamber of the moving part. At this time, the connecting needle completes the connection between the tube body and the liquid storage chamber, allowing the liquid amikacin stored in the liquid storage chamber to enter the tube body. After the liquid amikacin flows into the tube body, the connecting part and the moving part are completely removed from the tube body, and the connecting needle inserted into the cap of the tube body is directly pulled out. Subsequently, the operator inserts the blood collection needle into the finger of the person to be tested to collect peripheral blood and injects the collected blood into the tube body, thus completing one blood collection operation. In this solution, the connecting needle is fixed by the connecting part, so that when the connecting part of the shell is removed from the tube body, the needle is directly pulled out from the cap, preserving the complete tube body and cap body. The disassembly operation is simple and direct, facilitating subsequent rapid blood collection operations.

[0009] As a further improvement to the above technical solution, the moving part is provided with a second opening communicating with the liquid storage cavity at the direction of the communicating needle tube, and a sealing membrane is provided on the second opening, so that the communicating needle tube can be inserted into the sealing membrane and communicate with the liquid storage cavity.

[0010] By adopting the above technical solution, a sealing membrane is set at the second opening of the liquid storage chamber, which facilitates the connection of the connecting needle to the liquid storage chamber after passing through the sealing membrane, reducing the risk of connection failure due to inaccurate insertion of the connecting needle.

[0011] As a further improvement to the above technical solution, a sliding gap is formed between the outer periphery of the connecting part and the outer periphery of the moving part. A limiting band is wrapped around the sliding gap. The limiting band is detachably connected end to end. A plurality of first connecting blocks are arranged on the side of the limiting band near the connecting part. The end of the first connecting block opposite to the limiting band is detachably connected to the connecting part. A plurality of second connecting blocks are arranged on the side of the limiting band near the moving part. The end of the second connecting block opposite to the limiting band is detachably connected to the moving part.

[0012] To limit the slippage of the moving part relative to the connecting part during storage, the above-mentioned technical solution is adopted. The two sides of the limiting band are respectively pressed between the connecting part and the moving part, reducing the risk of the moving part accidentally touching the connecting needle tube and causing liquid amikacin to flow out of the outside through the connecting needle tube after it moves. After the shell is installed on the tube body, the two ends of the limiting band are disconnected and the entire limiting band is torn apart from the limiting gap. During this process, the first connecting block and the second connecting block on the limiting band are driven by the limiting band and break, thereby separating the limiting band from the connecting part and the moving part. When the limiting band is completely torn apart, the moving part can move up and down relative to the fixed connecting part in the limiting gap, so that the connecting needle tube can be inserted and connected to the moved moving part.

[0013] This design prevents relative movement between the moving parts and the connecting parts of the liquid storage assembly during storage, reducing the risk of liquid amikacin loss.

[0014] As a further improvement to the above technical solution, the moving part is provided with a sliding ring, and the connecting part is provided with an annular sliding groove, wherein the sliding ring is slidably assembled in the annular sliding groove.

[0015] By adopting the above technical solution, the sliding ring and the moving part slide synchronously. When the sliding ring moves on the connecting part, it restricts the movement of the moving part relative to the connecting part, thereby limiting the movement trajectory of the moving part and improving the stability of the connecting needle tube when it is inserted into the liquid storage cavity.

[0016] As a further improvement to the above technical solution, one end of the connecting needle tube that protrudes from the connecting part is located in the annular sliding groove, and a dustproof gap is formed between the sliding ring and the connecting part.

[0017] By adopting the above technical solution, the sliding ring is kept in the assembled state with the annular sliding groove, thereby forming a dustproof protection for the section between the connecting part and the moving part of the connecting needle tube. This prevents external impurities from flowing into the tube body through the connecting needle tube after flowing into the space between the connecting part and the moving part from the limiting band, thus achieving dustproof protection for the tube body.

[0018] As a further improvement to the above technical solution, the cover is provided with a punch hole, and an isolation diaphragm is provided on the bottom side of the punch hole. A snap ring is provided on the outer periphery of the end of the connecting part that passes through the punch hole, and the snap ring is snapped into the opening of the punch hole near the tube body.

[0019] By adopting the above technical solution, when installing the shell on the pipe body, the connecting part is directly inserted into the insertion hole of the cover until the snap ring is locked at the hole of the cover. The snap ring has a simple structure, which makes it easy for the operator to install and remove the connecting part.

[0020] As a further improvement to the above technical solution, the movable part is slidably mounted with a scraper in the liquid storage cavity, and a piston rod is connected to the scraper. The end of the piston rod away from the scraper extends away from the connecting part and then passes through to the outside of the movable part.

[0021] By adopting the above technical solution, when transferring liquid amikacin from the storage chamber to the tube, liquid is easily left on the inner wall of the storage chamber. Therefore, after moving the tube with a scraper, the liquid amikacin is injected into the tube, and the residual liquid amikacin on the inner wall of the storage chamber is scraped off, thereby improving the utilization rate of liquid amikacin.

[0022] As a further improvement to the above technical solution, a protective cover is provided on the end of the moving part where the piston rod protrudes from the moving part.

[0023] By adopting the above technical solution, the protective cover can protect the piston rod and prevent it from moving due to external impact during storage, which in turn causes the scraper to squeeze the liquid and cause changes in the internal pressure of the liquid storage chamber, thus reducing the risk of deformation of the liquid storage chamber.

[0024] As a further improvement to the above technical solution, the connecting part is made of transparent material, and the outer wall of the connecting part is provided with volume scale lines.

[0025] By adopting the above technical solution, the operator can observe the volume of liquid amikacin through the transparent material, which makes it easier to control the volume injected into the tube. Attached Figure Description

[0026] To more clearly illustrate the technical solutions in the embodiments of the present invention, the accompanying drawings used in the description of the embodiments will be briefly explained below. Obviously, the described drawings are only a part of the embodiments of the present invention, and not all of them. Those skilled in the art can obtain other design schemes and drawings based on these drawings without creative effort.

[0027] Figure 1 This is a schematic diagram of the overall structure of the blood collection tube according to an embodiment of this application; Figure 2 This is a cross-sectional view of a blood collection tube according to an embodiment of this application; Figure 3 yes Figure 2 A magnified view of A in the middle.

[0028] Attached icon number 1. Tube body; 11. Cap; 111. Puncture hole; 2. Liquid storage assembly; 21. Liquid storage chamber; 22. Connecting needle tube; 23. Connecting part; 231. Annular sliding groove; 232. Snap-fit ​​ring; 24. Moving part; 241. Sliding ring; 25. Sealing membrane; 26. Sliding gap; 3. Limiting band; 31. First connecting block; 32. Second connecting block; 4. Scraper; 41. Piston rod; 5. Protective cover. Detailed Implementation

[0029] Embodiments of the present invention are described in detail below. Examples of these embodiments are shown in the accompanying drawings, wherein the same or similar reference numerals denote the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.

[0030] In the description of this invention, it should be understood that the orientation descriptions, such as up, down, front, back, left, right, etc., are based on the orientation or positional relationship shown in the accompanying drawings. They are only for the convenience of describing this invention and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation. Therefore, they should not be construed as limiting this invention.

[0031] In the description of this invention, "several" means one or more, "more than" means two or more, "greater than," "less than," and "exceeding" are understood to exclude the stated number, while "above," "below," and "within" are understood to include the stated number. The use of "first" and "second" in the description is merely for distinguishing technical features and should not be construed as indicating or implying relative importance, or implicitly indicating the number of indicated technical features, or implicitly indicating the order of the indicated technical features.

[0032] In the description of this invention, unless otherwise explicitly defined, terms such as "set up," "install," and "connect" should be interpreted broadly, and those skilled in the art can reasonably determine the specific meaning of the above terms in this invention in conjunction with the specific content of the technical solution.

[0033] This embodiment is adapted to clinical blood collection and EDTA-dependent pseudothrombocytopenia sample correction testing scenarios, and specifically combines clinical blood collection operation specifications and medical consumables processing knowledge to supplement the working condition description.

[0034] See attached document Figure 1 Appendix Figure 2 and attached Figure 3The main body of this blood collection tube is divided into two major modules: tube body 1 and detachable liquid storage component 2. The top of tube body 1 has a first opening, and the first opening is sealed with a cover 11. The cover 11 has a pre-drilled hole 111, and an isolation membrane is set inside the hole 111 to separate the internal space of the blood collection tube from the external structure. The liquid storage assembly 2 consists of a shell and a connecting needle tube 22. The shell has a sealed liquid storage chamber 21 inside, which is pre-packaged with a quantitative amount of liquid amikacin. The shell is detachably snapped onto the outside of the cover 11 away from the tube body 1. One end of the connecting needle tube 22 penetrates the cover 11 through a puncture hole 111, pierces the isolation membrane, and connects to the inside of the tube body 1. The liquid storage chamber 21 can slide axially relative to the tube body 1. After the liquid storage chamber 21 is pushed toward the connecting needle tube 22, the other end of the connecting needle tube 22 can pierce the sealing structure of the liquid storage chamber 21, so that the liquid storage chamber 21 and the tube body 1 are connected. The amikacin in the chamber automatically flows into the blood collection tube, realizing pre-administration of medication before blood collection and avoiding the problem of poor platelet aggregation and dissociation caused by delayed medication after clinical blood collection.

[0035] Furthermore, the shell is divided into two sections: a connecting part 23 and a moving part 24. The connecting part 23 is detachably mounted on the cover 11 as a fixed base. The connecting needle tube 22 is fixedly installed inside the connecting part 23. The lower end of the connecting needle tube 22 passes through the cover 11 to connect the blood collection tube, and the upper end extends upward through the connecting part 23 and faces the moving part 24 above. The moving part 24 is slidably mounted on the upper end of the connecting part 23. The liquid storage chamber 21 is integrally formed and set inside the moving part 24. When the moving part 24 is pressed down, the moving part 24 slides down along the connecting part 23, and the upper end of the connecting needle tube 22 can be inserted into the liquid storage chamber 21 to complete the pipeline connection.

[0036] The movable part 24 has a second opening on the bottom surface of the connecting needle tube 22 that communicates with the liquid storage chamber 21. A thin medical sealing membrane 25 is provided at the second opening. When not in use, the sealing membrane 25 completely isolates the liquid storage chamber 21 to prevent amikacin from evaporating or leaking. When the movable part 24 is pressed down, the tip of the connecting needle tube 22 directly punctures the sealing membrane 25 to quickly establish a liquid flow channel. The sealing membrane 25 cannot be restored after being punctured once, ensuring that the medicine is used only once.

[0037] An annular sliding gap 26 is formed between the outer wall of the connecting part 23 and the outer wall of the moving part 24. A detachable limiting band 3 surrounds the gap, and the limiting band 3 is connected at both ends by tearing. A plurality of first connecting blocks 31 are arranged on the side of the limiting band 3 near the connecting part 23. The end of the first connecting block 31 facing away from the limiting band 3 is detachably connected to the connecting part 23. A plurality of second connecting blocks 32 are arranged on the side of the limiting band 3 near the moving part 24. The end of the second connecting block 32 facing away from the limiting band 3 is detachably connected to the moving part 24. During the product manufacturing, warehousing, and transportation stages, the limiting band 3 completely covers the sliding gap 26. After the connecting part 23 and the moving part 24 are connected by the first connecting block 31 and the second connecting block 32 respectively, the limiting band 3 can limit and constrain the moving part 24, preventing the moving part 24 from sliding downward and avoiding accidental contact during transportation that could cause the sealing film 25 to be punctured prematurely and the medicine to leak. Before clinical use, the ends of the limiting band 3 are torn open, and the limiting band 3 is peeled off outward. The first connecting block 31 and the second connecting block 32 are torn off and separated with the limiting band 3, releasing the sliding restriction of the moving part 24. Only then can the moving part 24 be pressed down to complete the drug administration operation.

[0038] The outer wall of the moving part 24 is integrally formed with an annular sliding ring 241, and the inner wall of the connecting part 23 is provided with a matching annular sliding groove 231. The sliding ring 241 is inserted into the sliding groove to achieve axial limiting sliding, which limits the moving part 24 to slide up and down only in the vertical direction, avoids the moving part 24 from deviating during the pressing process, and ensures that the connecting needle tube 22 is accurately aligned with the center of the sealing membrane 25 to puncture.

[0039] The upper end of the connecting needle tube 22 is arranged inside the annular sliding groove 231. A small dustproof gap is left between the sliding ring 241 and the groove wall of the connecting part 23. During daily storage, the dustproof gap prevents dust and debris from entering the sliding gap 26, preventing impurities from flowing into the blood collection tube with the drug solution and contaminating the blood sample.

[0040] A ring-shaped retaining ring 232 extends outward from the bottom end of the connecting part 23. When assembling the liquid storage component 2, the lower end of the connecting part 23 is inserted into the puncture hole 111 of the cover 11. The retaining ring 232 is locked in the inner wall of the hole 111 near the tube body 1. The elasticity of the retaining ring 232 enables quick assembly and disassembly. After the drug is administered, the entire liquid storage component 2 can be pulled up directly. The connecting needle tube 22 is pulled out from the puncture hole 111 of the cover 11 at the same time, leaving only the tube body 1 with the cover 11. Blood collection can be performed directly without the need to replace the tube cap. It is suitable for whole blood testing in automatic testing instruments.

[0041] A sliding scraper 4 is installed in the liquid storage chamber 21 inside the moving part 24. The scraper 4 is in close contact with the inner wall of the liquid storage chamber 21. A piston rod 41 is fixed in the center of the scraper 4. The piston rod 41 extends vertically upward through the top of the moving part 24. When administering medication, the piston rod 41 is pressed down, and the scraper 4 slides down along the inner wall of the liquid storage chamber 21 to scrape off residual amikacin adhering to the chamber wall, ensuring that the preset amount of medication flows into the blood collection tube and improving the accuracy of the medication dosage.

[0042] The piston rod 41 protrudes from the top of the moving part 24 and is fitted with a detachable protective cover 5. In the factory state, the protective cover 5 completely covers the end of the piston rod 41 to prevent accidental pushing of the piston rod 41 or squeezing of the scraper 4 during transportation, which would cause abnormal pressure in the cavity and prevent the liquid storage cavity 21 from bursting and leaking. When in use, the piston rod 41 can be pulled by removing the protective cover 5.

[0043] The connecting part 23 is made of transparent medical PVC material. Standard volume scale lines are printed on the outer wall of the connecting part 23 along the axis. Medical staff can directly observe the level of amikacin solution flowing through the connecting part 23, accurately control the amount of drug injected into the blood collection tube, and adapt to the blood collection needs of different blood collection tube specifications and different blood sample volumes.

[0044] The implementation principle of a blood collection tube according to an embodiment of this application is as follows: The liquid storage component 2 is fully assembled on the blood collection tube cap 11. The limiting band 3 is not torn open, the piston rod 41 protective cover 5 is intact, the moving part 24 is locked by the limiting band 3 and cannot move down, and the sealing film 25 completely seals the liquid storage cavity 21. Amikacin is sealed and stored without leakage or contamination. Medical staff tear open the limiting band 3, peel off and break the first and second connecting blocks 32, and release the sliding limit of the moving part 24; Press down on the moving part 24, and the sliding ring 241 slides down along the annular sliding groove 231. The upper end of the connecting needle tube 22 pierces the sealing membrane 25 at the bottom of the moving part 24, and the liquid storage chamber 21 is connected to the connecting needle tube 22 and the tube body 1. Remove the protective cover 5 at the top of the piston rod 41, and push the piston rod 41 to drive the scraper 4 to inject the liquid amikacin in the liquid storage chamber 21 into the blood collection tube. Pull the piston rod 41 to drive the scraper 4 to scrape the residual liquid on the inner wall of the liquid storage chamber 21. Observe the dosage through the scale of the transparent connecting part 23. Stop pressing after the standard dose is reached. Pull the liquid storage component 2 upward as a whole, the locking ring 232 disengages from the puncture hole 111 of the cover 11, the connecting needle tube 22 is pulled out simultaneously, and the isolation membrane of the cover 11 automatically closes to seal the puncture hole 111. The blood collection needle is pierced through the isolation membrane 11 of the cap, and the patient's blood is collected directly into the blood collection tube that has been pre-doped with amikacin. The blood mixes with the drug immediately upon entering the tube, which quickly inhibits EDTA-induced platelet aggregation. There is no need to wait for transportation or secondary drug addition in the laboratory, ensuring accurate test results. After drug administration, the reservoir component 2 can be uniformly classified and recycled as medical consumables, and the blood collection tube can independently complete the blood collection and testing process.

[0045] This embodiment enables pre-sealing of calibration drugs in blood collection tubes, allowing for quantitative drug administration in a single step before blood collection. This addresses the clinical pain points of delayed drug administration and poor dissociation effects in traditional blood collection methods. The sliding limiting structure ensures safe storage and transportation without leakage. The transparent scale and scraper structure precisely control the dosage of the drug. The assembly and disassembly are simple and suitable for standardized batch blood collection operations in the laboratory.

[0046] The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the embodiments described. Those skilled in the art can make various equivalent modifications or substitutions without departing from the spirit of the present invention, and these equivalent modifications or substitutions are all included within the scope defined by the claims of this application.

Claims

1. A blood collection tube, characterized in that, include: The tube has a first opening on its top side, and a cover is provided on the first opening. A liquid storage assembly includes a housing and a connecting needle tube. The housing has a hollow liquid storage cavity for storing liquid amikacin. The housing is detachably connected to the end of the cap opposite to the tube body. One end of the connecting needle tube is connected to the tube body. The liquid storage cavity is movable relative to the tube body and can be moved to the other end connected to the connecting needle tube.

2. A blood collection tube according to claim 1, characterized in that, The housing includes a connecting part and a movable part. The connecting part is detachably connected to the cover. The connecting needle tube is installed at the connecting part. The movable part is slidably installed on the side of the connecting part away from the cover. The liquid storage chamber is disposed in the movable part. The end of the connecting needle tube away from the tube body extends out of the connecting part and faces the movable part. The movable part can move to allow the connecting needle tube to penetrate into the liquid storage chamber.

3. A blood collection tube according to claim 2, characterized in that, The movable part is provided with a second opening that communicates with the liquid storage chamber at the direction of the connecting needle tube. The second opening is covered with a sealing membrane, and the connecting needle tube can be inserted into the sealing membrane to communicate with the liquid storage chamber.

4. A blood collection tube according to claim 2, characterized in that, A sliding gap is formed between the outer periphery of the connecting part and the outer periphery of the moving part. A limiting band is wrapped around the sliding gap. The ends of the limiting band are detachably connected. A plurality of first connecting blocks are arranged on the side of the limiting band near the connecting part. The ends of the first connecting blocks opposite to the limiting band are detachably connected to the connecting part. A plurality of second connecting blocks are arranged on the side of the limiting band near the moving part. The ends of the second connecting blocks opposite to the limiting band are detachably connected to the moving part.

5. A blood collection tube according to claim 2, characterized in that, The moving part is provided with a sliding ring, and the connecting part is provided with an annular sliding groove. The sliding ring is slidably assembled in the annular sliding groove.

6. A blood collection tube according to claim 5, characterized in that, One end of the connecting needle tube protruding from the connecting part is located in the annular sliding groove, and a dustproof gap is formed between the sliding ring and the connecting part.

7. A blood collection tube according to claim 5, characterized in that, The cover has a punch hole, and the cover has an isolation diaphragm on the bottom side of the punch hole. A snap ring is provided on the outer periphery of the end of the connecting part that passes through the punch hole, and the snap ring snaps into the opening of the punch hole near the tube body.

8. A blood collection tube according to claim 2, characterized in that, The movable part is equipped with a scraper that slides within the liquid storage chamber. A piston rod is connected to the scraper, and the end of the piston rod that is away from the scraper extends away from the connecting part and then passes through the movable part.

9. A blood collection tube according to claim 8, characterized in that, The movable part is covered with a protective cover at the end of the piston rod that protrudes from the movable part.

10. A blood collection tube according to claim 2, characterized in that, The connecting part is made of transparent material, and volume scale lines are provided on the outer wall of the connecting part.

Images